stoxline Quote Chart Rank Option Currency Glossary
  
InspireMD, Inc. (NSPR)
2.27  -0.03 (-1.3%)    03-18 16:00
Open: 2.16
High: 2.36
Volume: 51,181
  
Pre. Close: 2.3
Low: 2.16
Market Cap: 53(M)
Technical analysis
2024-03-18 4:46:07 PM
Short term     
Mid term     
Targets 6-month :  3.01 1-year :  3.31
Resists First :  2.58 Second :  2.83
Pivot price 2.55
Supports First :  2.16 Second :  1.79
MAs MA(5) :  2.38 MA(20) :  2.57
MA(100) :  2.74 MA(250) :  2.54
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  5.9 D(3) :  9.5
RSI RSI(14): 32.1
52-week High :  3.84 Low :  0.95
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NSPR ] has closed above bottom band by 1.5%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.36 - 2.38 2.38 - 2.39
Low: 2.12 - 2.14 2.14 - 2.16
Close: 2.24 - 2.27 2.27 - 2.3
Company Description

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Headline News

Fri, 15 Mar 2024
StockNews.com Begins Coverage on InspireMD (NYSE:NSPR) - MarketBeat

Fri, 15 Mar 2024
InspireMD (NYSE:NSPR) Now Covered by StockNews.com - Defense World

Thu, 07 Mar 2024
Earnings call: InspireMD boasts strong Q4 with record CGuard revenue By Investing.com - Investing.com Australia

Thu, 07 Mar 2024
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript - Yahoo Finance

Thu, 07 Mar 2024
InspireMD (NYSE:NSPR) Receives New Coverage from Analysts at StockNews.com - MarketBeat

Thu, 07 Mar 2024
InspireMD Full Year 2023 Earnings: Beats Expectations - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical Devices
Shares Out 23 (M)
Shares Float 10 (M)
Held by Insiders 20.1 (%)
Held by Institutions 44 (%)
Shares Short 80 (K)
Shares Short P.Month 96 (K)
Stock Financials
EPS -0.82
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.8
Profit Margin 0 %
Operating Margin -329.9 %
Return on Assets (ttm) -36.6 %
Return on Equity (ttm) -70.1 %
Qtrly Rev. Growth 71.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.26
EBITDA (p.s.) -0.9
Qtrly Earnings Growth 0 %
Operating Cash Flow -16 (M)
Levered Free Cash Flow -14 (M)
Stock Valuations
PE Ratio -2.77
PEG Ratio 0
Price to Book value 1.25
Price to Sales 8.57
Price to Cash Flow -3.26
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android